Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 1

Status

Active not recruiting 4Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Osteosarcoma 1Metastatic Bladder Urothelial Carcinoma 1Leiomyosarcoma 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 280Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × berzosertib × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

NCT04768296 2024-09-26

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

EMD Serono

Phase 2 Completed
76 enrolled 42 charts
Thoracic

Hereditary Sensory and Autonomic Neuropathies, Small Cell Lung Carcinoma

NCT03718091 2023-07-07

M6620 (VX-970) in Selected Solid Tumors

Massachusetts General Hospital

Phase 2 Completed
30 enrolled 15 charts
Sarcoma

Leiomyosarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡